Welcome to the UPF Digital Repository

Browsing Articles (Hospital del Mar Research Institute) by Author "Valderrama, Begoña P."

Browsing Articles (Hospital del Mar Research Institute) by Author "Valderrama, Begoña P."

Sort by: Order: Results:

  • Font, Albert; Ruiz de Porras, Vicenç; Valderrama, Begoña P.; Ramirez, Jose Luis; Nonell Mazelón, Lara; Virizuela, José Antonio; Anido, Urbano; González-Del-Alba, Aránzazu; Lainez, Nuria; Llorente, Maria Del Mar; Jiménez, Natalia; Mellado, Begoña; García-Donas, Jesús; Bellmunt Molins, Joaquim, 1959- (MDPI, 2021)
    In the phase II MAJA trial, maintenance therapy with vinflunine resulted in longer progression-free survival compared to best supportive care in advanced urothelial cell carcinoma (aUCC) patients who did not progress after ...
  • de Jong, Joep J.; Valderrama, Begoña P.; Perera Bel, Júlia; Juanpere, Nuria; Cejas, Paloma; Long, Henry; Albà Soler, Mar; Gibb, Ewan A.; Bellmunt Molins, Joaquim, 1959- (Nature Research, 2022)
    Background: molecular subtyping of bladder cancer has revealed luminal tumors generally have a more favourable prognosis. However, some aggressive forms of variant histology, including micropapillary, are often classified ...
  • Bellmunt Molins, Joaquim, 1959-; Valderrama, Begoña P.; Puente, Javier; Grande, Enrique; Bolós, M. Victoria; Lainez, Nuria; Vázquez, Sergio; Maroto, Pablo; Climent, Miguel Ángel; Garcia del Muro, Xavier; Arranz, José Ángel; Durán, Ignacio (Elsevier, 2022)
    Management of first-line advanced urothelial carcinoma (UC) has consisted during the past three decades in the administration of platinum-based chemotherapy followed by observation. Despite moderate to high response rates ...
  • Pal, Sumanta; Somford, Diederik M.; Grivas, Petros; Sridhar, Srikala S.; Gupta, Shilpa; Bellmunt Molins, Joaquim, 1959-; Sonpavde, Guru; Fleming, Mark T.; Lerner, Seth Paul; Loriot, Yohann; Hoffman-Censits, Jean; Valderrama, Begoña P.; Andresen, Corina; Schnabel, Marco J.; Cole, Suzanne; Daneshmand, Siamak (Future Medicine, 2022)
    PROOF 302 is an ongoing randomized, double-blind, placebo-controlled, adjuvant phase III trial (NCT04197986) in approximately 218 patients from 120 centers worldwide. Eligibility criteria include post-surgical high-risk ...

Search DSpace

Advanced Search


My Account

In collaboration with Compliant to Partaking